The Role of Epigenetic Modifications in Cancer Development and Progression: Potential Therapeutic Approaches DOI Creative Commons

Imtiaz Ali Soomro,

Quratulain Badar,

Wajid Ali

et al.

Indus journal of bioscience research., Journal Year: 2024, Volume and Issue: 3(1), P. 868 - 880

Published: Dec. 31, 2024

This research sought to explore the role of epigenetic changes in cancer initiation and progression, therapeutic potential modulators, i.e., DNMT inhibitors HDAC inhibitors, expression levels non-coding RNAs, miRNAs, controlling cells. The used a quantitative method, structured questionnaires regression analysis determine biology. validated that 65% respondents were familiar with DNA methylation, 60% histone modification, 55% gene-editing technologies like CRISPR. Chi-Square presence significant disparity awareness among demographic groups, p-values 0.02 0.05 for methylation by age modification medical specialty, respectively. Regression significantly caused cell apoptosis (β = 0.55, p 0.0002) suppressed migration -0.30, 0.02), while also 0.47, 0.005) promoted inhibition -0.25, 0.03). test miRNAs further correlations between miR-21 type (χ² 10.4, 0.02) miR-34a 12.1, 0.01). These results suggest therapies miRNA-based behavior enhancing efficacy. study highlights modifications cancer, urging on optimization.

Language: Английский

Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies DOI Creative Commons
Lenka Trnkova, Verona Buociková, Michal Mego

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 174, P. 116559 - 116559

Published: April 10, 2024

Breast cancer comprises a substantial proportion of diagnoses in women and is primary cause cancer-related mortality. While hormone-responsive cases generally have favorable prognosis, the aggressive nature triple-negative breast presents challenges, with intrinsic resistance to established treatments being persistent issue. The complexity intensifies emergence acquired resistance, further complicating management cancer. Epigenetic changes, encompassing DNA methylation, histone RNA modifications, non-coding RNAs, are acknowledged as crucial contributors heterogeneity unique epigenetic landscape harbored by each cellular component within tumor microenvironment (TME) adds great diversity intricate regulations which influence therapeutic responses. TME, sophisticated ecosystem non-cellular elements interacting cells, establishes an immunosuppressive fuels processes such growth, angiogenesis, extracellular matrix remodeling. These factors contribute challenging conditions treatment fostering hypoxic environment, inducing metabolic stress, creating physical barriers drug delivery. This article delves into complex connections between response, underlying vital interactions TME. To restore sensitivity treatment, it emphasizes need for combination therapies considering changes specific individual members Recognizing pivotal role epigenetics comprehending specificities TME essential devising more effective strategies. development reliable biomarkers patient stratification will facilitate tailored precise approaches.

Language: Английский

Citations

7
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives DOI Creative Commons

Ibrahim S. Alalhareth,

Saleh M. Alyami,

Abdulrhman Alshareef

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 207 - 207

Published: Feb. 3, 2025

Breast cancer is the most common malignancy affecting women, manifesting as a heterogeneous disease with diverse molecular characteristics and clinical presentations. Recent studies have elucidated role of epigenetic modifications in pathogenesis breast cancer, including drug resistance efflux characteristics, offering potential new diagnostic prognostic markers, treatment efficacy predictors, therapeutic agents. Key include DNA cytosine methylation covalent modification histone proteins. Unlike genetic mutations, reprogramming landscape epigenome promising targeted therapy for reversal resistance. Epidrugs, which target modifications, can provide novel options by reversing acquired to treatment. Currently, approach involves combination therapies consisting epidrugs immune checkpoint inhibitors. This review examines aberrant regulation initiation progression, focusing on related estrogen signaling, resistance, epithelial–mesenchymal transition (EMT). It existing drugs treating agents that modify DNA, inhibitors acetyltransferases, deacetylases, methyltransferases, demethyltransferases. also delves into ongoing combining other addresses upcoming obstacles this field.

Language: Английский

Citations

0
Epigenomic Echoes—Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse DOI Creative Commons
Anke Baumann, Zholdas Buribayev, Olaf Wolkenhauer

et al.

Epigenomes, Journal Year: 2025, Volume and Issue: 9(1), P. 5 - 5

Published: Feb. 5, 2025

Genomic and epigenomic instability are defining features of cancer, driving tumor progression, heterogeneity, therapeutic resistance. Central to this process epigenetic echoes, persistent dynamic modifications in DNA methylation, histone modifications, non-coding RNA regulation, chromatin remodeling that mirror underlying genomic chaos actively influence cancer cell behavior. This review delves into the complex relationship between these illustrating how they collectively shape genome, affect repair mechanisms, contribute evolution. However, dynamic, context-dependent nature changes presents scientific ethical challenges, particularly concerning privacy clinical applicability. Focusing on lung we examine specific patterns function as biomarkers for distinguishing subtypes monitoring disease progression relapse.

Language: Английский

Citations

0
Multi-omics and drug development DOI

Saira Hamid,

Ajaz A. Bhat,

Muzafar Rasool Bhat

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 147 - 171

Published: Jan. 1, 2025

Citations

0
Unravelling the epigenetic based mechanism in discovery of anticancer phytomedicine: Evidence based studies DOI
Bushra Bashir, Pranshul Sethi,

Satyajit Panda

et al.

Cellular Signalling, Journal Year: 2025, Volume and Issue: unknown, P. 111743 - 111743

Published: March 1, 2025

Language: Английский

Citations

0
The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences DOI Open Access

Sampath Rukshani Galappaththi,

Kelly R. Smith,

Enas S. Alsatari

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 13165 - 13165

Published: Dec. 7, 2024

Breast cancer is a significant health challenge worldwide and the most frequently diagnosed among women globally. This review provides comprehensive overview of breast biology, genomics, microbial dysbiosis, focusing on its various subtypes racial differences. primarily classified into carcinomas sarcomas, with constituting cases. Epidemiology risk factors are important for public intervention. Staging grading, based TNM Nottingham grading systems, respectively, crucial to determining clinical outcome treatment decisions. Histopathological include in situ invasive carcinomas, such as ductal carcinoma (IDC) lobular (ILC). The explores molecular subtypes, including Luminal A, B, Basal-like (Triple Negative), HER2-enriched, delves cancer's histological progression patterns. Recent research findings related nuclear mitochondrial genetic alterations, epigenetic reprogramming, role microbiome dysbiosis differences also reported. an update current diagnostics modalities.

Language: Английский

Citations

3
Roles of lncRNAs related to the p53 network in breast cancer progression DOI Creative Commons
Jiarui Song, Qiuxia Cui, Jidong Gao

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 16, 2024

The p53 is a crucial tumor suppressor and transcription factor that participates in apoptosis senescence. It can be activated upon DNA damage to regulate the expression of series genes. Previous studies have demonstrated some specific lncRNAs are part TP53 regulatory network. To enhance our understanding relationship between P53 cancers, we review localization, structure, function related mechanisms pathway or serve as transcriptional targets.

Language: Английский

Citations

2
Unlocking the epigenetic code: new insights into triple-negative breast cancer DOI Creative Commons
Gowthami Mahendran,

Ann Dharshika Shangaradas,

Ricardo Romero-Moreno

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 18, 2024

Triple-negative breast cancer (TNBC) is a highly aggressive and clinically challenging subtype of cancer, lacking the expression estrogen receptor (ER), progesterone (PR), HER2/neu. The absence these receptors limits therapeutic options necessitating exploration novel treatment strategies. Epigenetic modifications, which include DNA methylation, histone microRNA (miRNA) regulation, play pivotal role in TNBC pathogenesis represent promising targets. This review delves into potential epigenetic interventions TNBC, with focus on miRNA therapeutics. We examine methylation gene silencing within development inhibitors designed to reactivate silenced tumor suppressor genes. Histone through deacetylation acetylation particular, are critical regulating expression. explore efficacy deacetylase (HDACi), have shown promise reversing aberrant patterns, thereby restoring normal function, suppressing growth. Furthermore, highlights dual miRNAs as both oncogenes suppressors discusses mimics modulating regulatory molecules inhibit progression. By integrating therapies, we propose multifaceted approach target underlying mechanisms that drive synergistic use inhibitors, HDACi, miRNA-based therapies offers avenue for personalized strategies, aiming enhance clinical outcome patients TNBC.

Language: Английский

Citations

2
The chromatin remodeler DEK promotes proliferation of mammary epithelium and is associated with H3K27me3 epigenetic modifications DOI
Megan Johnstone,

Ashley Leck,

Taylor E. Lange

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 10, 2024

The DEK chromatin remodeling protein was previously shown to confer oncogenic phenotypes human and mouse mammary epithelial cells using

Language: Английский

Citations

1
MOLEKULINIAI MECHANIZMAI, LEMIANTYS KARCINOMOS IN SITU VYSTYMĄSI DOI Open Access

Dominyka Naudužaitė

Health Sciences, Journal Year: 2024, Volume and Issue: 35(5), P. 213 - 214

Published: Aug. 1, 2024

Karcinomos in situ, įskaitant lobulinę karcinomą situ (LCIS) ir duktalinę (DCIS) vystymasis susijęs su sudėtingais molekuliniais mechanizmais, kurie prisideda prie šių neinvazinių krūties pažeidimų atsiradimo progresavimo. Straipsnyje nagrinėjami molekuliniai mechanizmai, lemiantys karcinomos vystymąsi, jie gali skirtis priklausomai nuo carcinoma konkretaus potipio išsivystymo aplinkybių. Aiškus molekulinių mechanizmų, susijusių vėžinių ląstelių vystymusi, supratimas galėtų padėti nustatyti koreguoti genetines mutacijas, kad būtų galima valdyti dalijimosi sutrikimus.

Citations

0